Drug Discovery

Bioharmony, Boehringer to advance bacteriophage lysin therapeutics to treat MDR bacterial infections

Bioharmony Therapeutics, a biopharmaceutical company focusing on the development of novel therapeutics for hard to treat bacterial infections, has entered into a collaborative research and licensing agreement with Boehringer Ingelheim to develop bacteriophage lysins for the treatment of multidrug resistant (MDR) Acinetobacter infections, a frequent cause of hospital-acquired pneumonia and life-threatening blood or wound infections.

Ascletis and Alphamab sign licensing deal for anti-PD-L1 to treat hepatitis B and other viral diseases

Ascletis Pharma (Ascletis, 1672.HK) and Suzhou Alphamab jointly announce that Ascletis' subsidiary and Alphamab have entered into a strategic collaboration and exclusive licensing agreement for anti-PD-L1 KN035 to treat hepatitis B and other viral diseases in Greater China (Ascletis code: ASC22).

Charles River, Atomwise collaborate on AI-driven drug discovery

Charles River Laboratories International has collaborated with Atomwise on integrated and artificial intelligence (AI)-driven drug discovery.

Agenus to use Selexis’ technology to produce therapeutic proteins

Selexis has expanded its alliance with clinical-stage immuno-oncology company Agenus by signing additional commercial license agreements (CLAs).

Elevian, Insilico collaborate to discover drugs for aging

Elevian and Insilico Medicine have announced a research and development partnership to develop oral medications targeting the GDF11 pathway and associated targets.

CANbridge, WuXi expand rare disease partnership

CANbridge Pharmaceuticals and WuXi Biologics have expanded their rare disease therapeutics partnership to enable the former to discover, develop and commercialize four additional drug candidates.

Pfizer to utilize CytoReason’s machine learning model for drug discovery

Pfizer has signed a collaboration agreement to use CytoReason’s machine learning model of the immune system for drug discovery.

Gilead, Yuhan to co-develop new therapies for NASH in $785m deal

Gilead Sciences has signed a licensing and collaboration agreement, potentially worth $785m, with South Korea-based Yuhan to develop new therapeutic candidates for the treatment of advanced fibrosis due to nonalcoholic steatohepatitis (NASH).

Adaptive, Genentech to collaborate on personalized cellular therapies for cancer

Adaptive Biotechnologies has entered into a worldwide collaboration and license agreement with Roche Group’s Genentech to develop, manufacture and commercialize novel neoantigen directed T-cell therapies for the treatment of a range of cancers.